What do we already know about this topic?

• To date, there are no real-world studies that validate the efficacy and safety of ubrogepant, lasmiditan, and rimegepant in a patient population with complex comorbidities, chronic migraine, multiple ineffective treatment trials, and concurrent usage of other acute and preventive medications.

How was this study conducted?

• Prospective, real-world study of adult patients with migraine with or without aura (N=100) who were prescribed and had taken at least one dose of ubrogepant, rimegepant and lasmiditan at the Mayo Clinic, Arizona, USA.
• Each patient underwent a medical chart review and completed a structured questionnaire (15 questions) approximately 1–3 months after treatment was prescribed.